Details for Patent: 12,629,377
✉ Email this page to a colleague
Which drugs does patent 12,629,377 protect, and when does it expire?
Patent 12,629,377 protects SUBVENITE and is included in one NDA.
Summary for Patent: 12,629,377
| Title: | Lamotrigine oral liquid suspension and use thereof |
| Abstract: | The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration. |
| Inventor(s): | Paul Sudhakar, Scott Boyer |
| Assignee: | OWP Pharmaceuticals Inc |
| Application Number: | US18/752,293 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Device; Dosage form; |
Drugs Protected by US Patent 12,629,377
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF EPILEPSY AS ADJUNCTIVE THERAPY IN PATIENTS 2 YEARS AND OLDER WITH PARTIAL-ONSET SEIZURES, PRIMARY GENERALIZED TONIC-CLONIC SEIZURES, OR GENERALIZED SEIZURES OF LENNOX-GASTAUT SYNDROME | ⤷ Start Trial | |||
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | CONVERSION TO MONOTHERAPY IN ADULTS 16 YEARS AND OLDER WITH PARTIAL-ONSET SEIZURES WHO ARE RECEIVING CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, PRIMIDONE, OR VALPROATE AS THE SINGLE ANTIEPILEPTIC DRUG | ⤷ Start Trial | |||
| Owp Pharms | SUBVENITE | lamotrigine | SUSPENSION;ORAL | 218879-001 | Sep 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
